Nuvation Bio Inc : Tumors Shrank in 91% of Taletrectinib-Treated Patients With Advanced Ros1-Positive Nsclc Who Were Ros1 Tki-Naïve
Nuvation Bio Inc:在接受他樂替尼治療的晚期 Ros1 陽性非小細胞肺癌患者中,有 91% 的患者腫瘤萎縮,這些患者是 Ros1 Tki-Naíve
Nuvation Bio Inc : Tumors Shrank in 91% of Taletrectinib-Treated Patients With Advanced Ros1-Positive Nsclc Who Were Ros1 Tki-Naïve
Nuvation Bio Inc:在接受他樂替尼治療的晚期 Ros1 陽性非小細胞肺癌患者中,有 91% 的患者腫瘤萎縮,這些患者是 Ros1 Tki-Naíve
譯文內容由第三人軟體翻譯。